Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Savreet K. Sandhu"'
Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
Autor:
Yoong Wearn Lim, Garry L. Coles, Savreet K. Sandhu, David S. Johnson, Adam S. Adler, Erica L. Stone
Publikováno v:
BMC Biology, Vol 19, Iss 1, Pp 1-17 (2021)
Abstract Background The anti-tumor activity of anti-PD-1/PD-L1 therapies correlates with T cell infiltration in tumors. Thus, a major goal in oncology is to find strategies that enhance T cell infiltration and efficacy of anti-PD-1/PD-L1 therapy. TGF
Externí odkaz:
https://doaj.org/article/00fd9007a4614376a1b047d12d4c3430
Autor:
Erica L Stone, Kyle P Carter, Ellen K Wagner, Michael A Asensio, Emily Benzie, Yao Yuan Chiang, Garry L Coles, Chelsea Edgar, Bishal K Gautam, Ashley Gras, Jackson Leong, Renee Leong, Vishal A Manickam, Rena A Mizrahi, Ariel R Niedecken, Jasmeen Saini, Savreet K Sandhu, Jan Fredrick Simons, Kacy Stadtmiller, Brendan Tinsley, LaRee Tracy, Nicholas P Wayham, Yoong Wearn Lim, Adam S Adler, David S Johnson
Publikováno v:
Cancer Immunology Research. 10:A32-A32
Anti-CTLA-4 antibodies such as ipilimumab were among the first immuno-oncology agents to show significantly improved outcomes for patients. However, existing anti-CTLA-4 therapies fail to induce a response in a majority of patients and can induce sev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa01c69f115a5cbabbd7bbb2e0b1ad8b
https://doi.org/10.1158/2326-6074.tumimm22-a32
https://doi.org/10.1158/2326-6074.tumimm22-a32
Autor:
Kyle P Carter, Yao Y. Chiang, Vishal A. Manickam, Emily Benzie, Nicholas Wayham, David S. Johnson, Rena A. Mizrahi, Jasmeen Saini, Garry L. Coles, Savreet K. Sandhu, Eric A. Stone, Jan Fredrick Simons, Adam S. Adler, Ellen K. Wagner, Ashley Gras, Chelsea Edgar, LaRee Tracy, Brendan Tinsley, Jackson Leong, Kacy Stadtmiller, Ariel R Niedecken, Renee Leong, Yoong Wearn Lim, Bishal K. Gautam, Michael A. Asensio
Anti-CTLA-4 antibodies such as ipilimumab were among the first immune-oncology agents to show significantly improved outcomes for patients. However, existing anti-CTLA-4 therapies fail to induce a response in a majority of patients and can induce sev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f6edafd41945bb756870a8746a1366a
https://doi.org/10.1101/2021.07.12.452090
https://doi.org/10.1101/2021.07.12.452090
Autor:
Yoong Wearn Lim, Coles, Garry L., Savreet K. Sandhu, Johnson, David S., Adler, Adam S., Stone, Erica L.
Additional file 1. Supplementary figures. Figure S1. Anti-PD-L1 plus anti-TGF-β in the murine tumor model HuPD-L1-MC38. Figure S2. Anti-PD-L1 plus anti-TGF-β in the murine tumor model CT26. Figure S3. Quality control of single cell RNA-seq of anti-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::209476836037e3f3376d139e70dc4c88
Single cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
Autor:
Savreet K. Sandhu, Adam S. Adler, Yoong Wearn Lim, Garry L. Coles, David S. Johnson, Eric A. Stone
BackgroundThe anti-tumor activity of anti-PD-1/PD-L1 therapies correlates with T cell infiltration in tumors. Thus, a major goal in oncology is to find strategies that enhance T cell infiltration and efficacy of anti-PD-1/PD-L1 therapy. TGF-β has be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57f67589a2e645cac156d897748634aa
https://doi.org/10.1101/2020.11.13.382358
https://doi.org/10.1101/2020.11.13.382358
Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
Autor:
Adam S. Adler, Yoong Wearn Lim, David S. Johnson, Garry L. Coles, Savreet K. Sandhu, Eric A. Stone
Publikováno v:
BMC Biology
BMC Biology, Vol 19, Iss 1, Pp 1-17 (2021)
BMC Biology, Vol 19, Iss 1, Pp 1-17 (2021)
Background The anti-tumor activity of anti-PD-1/PD-L1 therapies correlates with T cell infiltration in tumors. Thus, a major goal in oncology is to find strategies that enhance T cell infiltration and efficacy of anti-PD-1/PD-L1 therapy. TGF-β has b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc70ae0715b7fc57ababe5a965772c7e
https://pubmed.ncbi.nlm.nih.gov/34030676
https://pubmed.ncbi.nlm.nih.gov/34030676
Autor:
Adam S. Adler, Garry L. Coles, David S. Johnson, Eric A. Stone, Savreet K. Sandhu, Yoong Wearn Lim
Publikováno v:
Cancer Research. 81:2684-2684
Background: The anti-tumor activity of anti-PD-1/PD-L1 therapies correlates with T cell infiltration in tumors. Thus, a major goal in oncology is to find strategies that enhance T cell infiltration and efficacy of anti-PD-1/PD-L1 therapy. TGF-β has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdd606ab2fe911c850ee353470af0734
https://doi.org/10.1158/1538-7445.am2021-2684
https://doi.org/10.1158/1538-7445.am2021-2684